RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Fresh Insights Into the Practicalities of Developing Biosimilar Biologics

Fresh Insights Into the Practicalities of Developing Biosimilar Biologics

Posted 01 October 2009 | By

Biotech products coming off patent afford a window of opportunity to obtain a marketing approval for a "follow-on biologic" by a new product developer. If the supporting data are sufficient to authorize interchangeability and substitution, the new product is defined as a similar biologic or "biosimilar." Europe is leading the way in defining the regulatory pathway for biosimilars. This article shares lessons learned that can provide strategic insights to guide biosimilar development plans.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.